Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
PAION announces submission of the Marketing Authorization Application for remimazolam in procedural sedation to the European Medicines Agency
PAION AG invites to shareholder evening
PAION announces attendance at three upcoming conferences
PAION AG reports financial results for the first half-year of 2019
FDA accepts filing of NDA for Remimazolam in the U.S.
Annual general Meeting approves all agenda items and elects Dr. Leyck Dieken to the Supervisory Board
PAION AG reports on fiscal year 2018
PAION AG announces attendance at four upcoming conferences